Cullinan Therapeutics Inc. recently provided an update on their ongoing research and development efforts at the ASCO 2025 event, focusing on Zipalertinib. The presentation highlighted the REZILIENT1 results overview, strategic perspectives, and next steps for the treatment of EGFR ex20ins NSCLC. Key speakers included Nadim Ahmed, Jeff Jones, MD, MBA, and Danny Nguyen, MD. The company also discussed its ongoing clinical programs, including CLN-049 for AML & MDS and CLN-617 for solid tumors, emphasizing their potential in various therapeutic areas. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.